Darunavir

Fidelia Bernice, Pharm.D., BCIDP
Pediatric Dosing Author: Bethany Sharpless Chalk, Pharm.D., BCPPS

Darunavir is a topic covered in the Johns Hopkins HIV Guide.

To view the entire topic, please log in or purchase a subscription.

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

A COVID-19 Conversation - Variants, Vaccines, and Long-Term Effects

Coronavirus COVID-19 (SARS-CoV-2)

Suicide Risk in the COVID-19 Pandemic

Moderna COVID-19 Vaccine

BNT162b2 COVID-19 Vaccine (BioNTech/Pfizer)

Managing Stress and Coping with COVID-19

Johnson & Johnson COVID-19 Vaccine

-- The first section of this topic is shown below --

INDICATIONS

FDA

HIV-infected patients who are treatment-experienced and have at least one DRV resistance mutation, in combination with other antiretrovirals (DRV/r 600/100 mg twice daily).
HIV-infected patients who are treatment-naive (DRV/r 800/100 mg once daily or DRV/c 800/150 mg once daily).
HIV-infected children (>3 years)

-- To view the remaining sections of this topic, please log in or purchase a subscription --

INDICATIONS

FDA

HIV-infected patients who are treatment-experienced and have at least one DRV resistance mutation, in combination with other antiretrovirals (DRV/r 600/100 mg twice daily).
HIV-infected patients who are treatment-naive (DRV/r 800/100 mg once daily or DRV/c 800/150 mg once daily).
HIV-infected children (>3 years)

There's more to see -- the rest of this entry is available only to subscribers.